News - Research, Inflammatory diseases


Popular Filters

1 to 25 of 27 results

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study

Amgen and AstraZeneca’s brodalumab meets all endpoints in Ph III study


Anglo-Swedish drug major AstraZeneca and the USA’s Amgen have announced that the Phase III AMAGINE-1…

AmgenAstraZenecaBiotechnologybrodalumabInflammatory diseasesResearch

$5 million milestone for India’s Glenmark from Sanofi

$5 million milestone for India’s Glenmark from Sanofi


Indian drugmaker Glenmark Pharmaceuticals says it has informed the Stock Exchange that it has received…

FinancialGlenmark PharmaceuticalsInflammatory diseasesPharmaceuticalResearchSanofi

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California


MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site


Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

NovaSAID partners with Cadila to develop inflammation and pain therapies


Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

Shield Therapeutics’ ST10 delivers robust results in AEGIS Ph III program


Independent UK pharma firm Shield Therapeutics has announces strongly positive top-line data from the…

HematologyInflammatory diseasesPharmaceuticalResearchShield TherapeuticsST10

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients


Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development


At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease


Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Teijin and Amgen join forces on autoimmune disease research


Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

XOMA's partner Servier launches proof-of-concept clinical program for gevokizumab


US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker…

Anti-Arthritics/RheumaticsgevokizumabInflammatory diseasesPharmaceuticalResearchServierXOMA Corp

Teva and Active Biotech to move forward with laquinimod on positive Ph IIa results in active lupus nephritis


Israel's Teva Pharmaceutical Industries (NYSE: TEVA) and Swedish partner Active Biotech (OMX NORDIC:…

Active BiotechInflammatory diseaseslaquinimodNephrology and HepatologyPharmaceuticalResearchTeva Pharmaceutical Industries

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease


US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

Concert Pharma in $300 million-plus deal with Celgene


Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

AstraZeneca plans more job cuts; inks $240M-plus deal with Moderna; expands alliance with Karolinska Institutet


Anglo-Swedish drug major AstraZeneca (LSE: AZN), ahead of its Investor Day briefing in New York later…

AstraZenecaCardio-vascularFinancialImmunologicalsInflammatory diseasesLicensingModerna TherapeuticsOncologyPharmaceuticalResearch

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S


Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Novo Nordisk collaborates with Oxford University on RA and other inflammatory diseases research


Departing from its core competence, diabetes, Danish insulin giant Novo Nordisk (NOV: N) and the Kennedy…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceuticalResearch

Actelion drops setipiprant, gets miglustat approval in Japan


Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

GSK exercises option for Galapagos drug candidates


Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

BioLineRx inks deal with Compugen


Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

New start-up TopiVert gets $12.5 million funding


UK investment group Imperial Innovations (AIM: IVO) and SV Life Sciences have committed to invest £8…

FinancialInflammatory diseasesJohnson & JohnsonPharmaceuticalResearchRespiVertTopiVert

1 to 25 of 27 results

Back to top